Recently, the U.S. FDA (Food and Drug Administration) approved the first cannabis-based medication called as Epidiolex. This approved drug is now obtainable by prescription in all 50 states.
The twice-daily oral medication is permitted for the patients 2 and older to cure two forms of epileptic syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. Dravet syndrome is an unusual genetic dysfunction of the brain that starts in the primary years of life, whereas, Lennox-Gastaut syndrome is a type of epilepsy with many types of attacks that initiates in early childhood, typically between 3 Year and 5 Year. Justin Gover—CEO of GW Pharmaceuticals and the producer of Epidiolex—in a written statement reported that as the patients have traditionally not reacted well to existing seizure medications, there was a dreadful need for new treatments that goal to decrease the frequency and impact of seizures. Gover further added that the company is committed to making sure that these patients can get this novel cannabinoid medicine that has been carefully studied in clinical trials, produced to assure consistency and quality, and is qualified to be enclosed by insurance for appropriate patients.
Recently, FDA was also in news for its announcement of recalling of dry pet foods. Two companies are willingly recalling dry pet food, due to increased levels of vitamin D. The recall influences products from Nutrisca and Natural Life Pet Foods, according to the FDA. Reportedly, Natural Life Pet Products is recalling 17.5 Lbs bags of its chicken and potato dry dog foodstuff that were issued to retailers in California, Alabama, Florida, Georgia, South Carolina, North Carolina, Virginia, and Tennessee. Also recalled, owing to increased levels of vitamin D, is Nutrisca’s 1 formula of dry dog food. The recall influences Nutrisca chicken and chickpea dry dog food in 4, 15, and 28 Lbs bags that were issued nationwide.